A股方面，医药股集体调整；苏超持续火爆，金陵体育收获3个20%涨停，共创草坪4连板；兵装重组概念涨幅位居两市第一，建设工业、东安动力 涨停。 港股新消费三宝，泡泡玛特、老铺黄金、蜜雪集团集体跳水。 截至收盘 ， 沪指涨0.23% ， 深成指涨0.58% ， 创业板指涨1.17% ，全市场成交额13170亿元 ， 较上日放量1395亿元 。 全市场2600只个股 上涨。 01 新消费三宝 集体跳水 港股新消费迎来大跌，老铺黄金跳水，蜜雪集团杀跌，泡泡玛特亦在创下新高之后快速回落。截至发稿，老铺黄金跌9%，蜜雪集团跌7%，泡泡玛 特跌1%。 近期，新消费涨幅巨大，此前老铺黄金涨幅已达23倍，泡泡玛特过去两年半时间从每股8.6港元附近飙升到256港元，今年以来涨幅惊人。一时 间，新消费取代茅台的声音不绝于耳。然而，从估值来看，泡泡玛特的市盈率（TTM）已达96倍，老铺黄金更达99倍，蜜雪集团亦达46倍，实属 不低。 这次，这些股票杀跌，其实也有流动性的原因。近期，市场虽然不断上行，但成交量并没有有效放大。这意味着，其中存量博弈的成分还是比较 高。建银国际研究报告指出，香港市场流动性指数过去一个月下滑，支持指数的是更 ...

金十图示：2025年06月05日（周四）富时中国A50指数成分股午盘收盘行情一览：券商股上涨，消费电子涨幅较大 NTS CURC AHIN 2054.84亿市值 1774.29亿市值 1.88亿成交额 4.89亿成交额 7.16 22.09 +0.01(+0.14%) +0.23(+1.05%) @ JIN10.COM 金十数据 | 一个交易工具 HN10.COM 保险 队 中国人保 中国太保 中国平安 081 3714.82亿市值 3379.63亿市值 9828.06亿市值 5.19亿成交额 15.08亿成交额 4.54亿成交额 35.13 53.97 8.40 +0.04(+0.11%) +0.21(+0.39%) +0.10(+1.20%) 酸酒行业 贵州茅台 山西汾酒 五粮液 18961.68亿市值 2201.55亿市值 4852.01亿市值 19.05亿成交额 8.02亿成交额 15.42亿成交额 1509.45 125.00 180.46 -0.51(-0.03%) +1.28(+0.71%) +0.45(+0.36%) 半导体 北方华创 寒武纪-U 2273.98亿市值 2539.97亿市值 3 ...

金凯生科股东青松投资持有公司股份4,801,374股(占公司总股本比例3.99%)。青松投资计划通过集中竞 价方式减持公司股份不超过1,204,000股，减持比例不超过公司总股本的1%。集中竞价的减持期间为自 本减持计划公告之日起十五个交易日后的三个月内。 中国经济网北京6月5日讯金凯生科（301509）(301509.SZ)昨晚披露的关于公司股东减持股份的预披露 公告显示，公司于近日分别收到股东启鹭(厦门)股权投资合伙企业(有限合伙)(以下简称"启鹭投资")、青 岛青松创业投资集团有限公司-青岛松凯创业投资企业(有限合伙)(以下简称"青松投资")提交的《关于减 持金凯(辽宁)生命科技股份有限公司股份计划的告知函》。 金凯生科股东启鹭投资持有公司股份7,140,500股(占公司总股本比例5.93%)。启鹭投资计划通过集中竞 价和大宗交易方式减持公司股份不超过3,612,000股(占公司总股本比例3%)。其中，通过集中竞价方式减 持股份不超过1,204,000股，减持比例不超过公司总股本的1%；通过大宗交易方式减持股份不超过 2,408,000股，减持比例不超过公司总股本的2%。集中竞价或大宗交易的减持期间为自 ...

Core Viewpoint - The pharmaceutical sector experienced a significant net outflow of over 2.1 billion yuan, while other sectors like communication and cultural media saw net inflows [1][2]. Group 1: Sector Performance - The communication sector had a net inflow of 8.12 billion yuan, with a net inflow rate of 3.07% [2]. - The cultural media sector recorded a net inflow of 7.67 billion yuan, with a net inflow rate of 3.90% [2]. - The pharmaceutical sector faced the largest net outflow, totaling 21.08 billion yuan, with a net outflow rate of -3.75% [2]. Group 2: Top Stocks by Net Inflow - The top stock by net inflow was Zhongji Xuchuang, with a net inflow of 4.28 billion yuan and a net inflow rate of 14.23% [3]. - Xue Ren Shares followed with a net inflow of 3.34 billion yuan and a net inflow rate of 11.14% [3]. - N Zhongce had a net inflow of 3.12 billion yuan, with a notable net inflow rate of 18.73% [3]. Group 3: Top Stocks by Net Outflow - The stock with the highest net outflow was Zhongke Jincai, with a net outflow of 2.34 billion yuan and a net outflow rate of -10.10% [4]. - Jiu Zhi Tang experienced a net outflow of 1.95 billion yuan, with a net outflow rate of -21.64% [4]. - Shangluo Electronics had a net outflow of 1.93 billion yuan, with a net outflow rate of -28.67% [4].

东兴证券指出，在指数维持区间震荡的前提下，建议维持中等仓位，可参与市场结构性投资的机会。在 7月之前市场有望维持大的区间震荡走势，由于市场成交量维持在较低水平，市场成交难以支撑大市值 板块持续上涨，因此，市场热点轮动态势将会十分明显，即使人工智能、机器人等产业向好的主线，目 前量能情况下也难有整体性上涨基础，因此，积极参与主线轮动将是较为合理的策略。在二季度存在业 绩压力的预期下，对于低估值板块可逢低布局，随着利率持续下行，机构资金尤其是中长线资金配置的 方向仍在低估值高分红板块。一旦进入6月之后，市场开始重新回归业绩预期，低估值板块有望迎来恢 复性反弹。 中原证券认为，周三A股市场高开高走、小幅震荡上行，早盘股指高开后震荡上行，盘中沪指在3378点 附近遭遇阻力，午后股指维持震荡，盘中消费电子、互联网服务、证券以及有色金属等行业表现较好； 航空机场、物流、航天航空以及化学制药等行业表现较弱，沪指全天基本呈现小幅震荡上行的运行特 征。当前上证综指与创业板指数的平均市盈率分别为13.78倍、36.16倍，处于近三年中位数平均水平， 适合中长期布局。两市周三成交金额11776亿元，处于近三年日均成交量中位数区域上 ...

分析师：张刚 登记编码：S0730511010001 zhanggang@ccnew.com 021-50586990 电子消费行业领涨 A 股小幅上行 ——市场分析 相关报告 《市场分析：金融消费行业领涨 A 股震荡上 行》 2025-06-03 《市场分析：银行医药行业领涨 A 股震荡整 固》 2025-05-30 《市场分析：成长行业领涨 A 股震荡上行》 2025-05-29 联系人： 李智 | | | 证券研究报告-市场分析 发布日期：2025 年 06 月 04 日 风险提示：海外超预期衰退，影响国内经济复苏进程；国内政 策及经济复苏进度不及预期；宏观经济超预期扰动；政策超预期 变化；国际关系变化带来经济环境变化；海外宏观流动性超预期 收紧；海外波动加剧。 本报告版权属于中原证券股份有限公司 www.ccnew.com 请阅读最后一页各项声明 第1页 / 共7页 地址： 郑州郑东新区商务外环路10 号18 楼 地址： 上海浦东新区世纪大道 1788 号 T1 座 22 楼 投资要点： ◼ A 股市场综述 周三（06 月 04 日）A 股市场高开高走、小幅震荡上行，早盘股指高 开后震荡上行，盘中沪指 ...

Core Viewpoint - The article discusses the acquisition of control over listed companies, specifically highlighting the acquisition of 23% of Yiming Pharmaceutical by Yao Jinbo for 662 million yuan, indicating a trend of control changes among various listed companies in 2023 [1][2]. Group 1: Yiming Pharmaceutical Acquisition - Yao Jinbo's company plans to acquire 23% of Yiming Pharmaceutical at a price of 15.10 yuan per share, representing a 24% premium over the last closing price of 12.18 yuan [1][3]. - After the acquisition, the actual controller of Yiming Pharmaceutical will change from Gao Fan to Yao Jinbo, who holds 99% of the shares in the acquiring company [3][4]. - The transaction includes performance guarantees, with Yiming Pharmaceutical committing to maintain annual audited revenue of no less than 600 million yuan and net profit of no less than 30 million yuan for the next three years [4]. Group 2: Financial Performance of Yiming Pharmaceutical - Yiming Pharmaceutical's revenue and net profit saw significant declines in 2023, with revenue down 22.14% and net profit down 65.14% year-on-year [5]. - In 2024, the company reported revenue of 652 million yuan, a slight decline of 2.27%, but net profit increased by 198.5% to 45.93 million yuan [5]. - The company heavily relies on a single product, Miglitol tablets, which accounted for 72.72% of its revenue, raising concerns about its vulnerability to market changes [5]. Group 3: Broader Market Trends - Several listed companies have announced changes in control this year, with buyers including industrial capital, state-owned enterprises, and private equity firms [1][6]. - For instance, Filinger announced a change in control with significant share transfers to industrial capital and private equity [7][8]. - The trend indicates a growing involvement of state-owned and industrial entities in acquiring control of listed companies, reflecting a shift in market dynamics [9][10].

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical and biotechnology sector [5] Core Insights - The blood purification device industry is benefiting from an aging population and increasing treatment penetration rates, with hemodialysis being the primary treatment for end-stage renal disease (ESRD) [2][12] - The domestic substitution trend in the blood purification device industry is accelerating, with local brands gradually rising to compete with foreign brands [2][33] - The market for blood purification devices is expected to grow significantly, driven by the increasing number of ESRD patients and the low treatment penetration rate in China compared to developed countries [17][19] Summary by Sections Market Performance - The pharmaceutical sector outperformed the overall market, with a 2.21% increase in the biopharmaceutical sector, while the overall A-share market declined by 0.05% [1][60] - The TTM price-to-earnings ratio for the biopharmaceutical sector is 34.03x, which is at the 69.61% percentile of the historical valuation over the past five years [1][67] Industry Analysis - The global ESRD patient population is projected to grow from 1113.86 million in 2023 to 1328.60 million by 2027, with a compound annual growth rate (CAGR) of 4.51% [17] - In China, the number of ESRD patients receiving dialysis treatment is significantly lower than in developed countries, indicating substantial growth potential in treatment penetration [19][30] Competitive Landscape - Foreign brands dominate the blood purification device market, with companies like Fresenius and Baxter holding significant market shares, but domestic brands are rapidly gaining ground [2][33] - Major domestic players include Weigao Blood Purification, Shandong Mountain, and Jianfan Biological, which are expanding their market presence through innovation and product development [2][41][45] Company Forecasts and Ratings - Major companies in the sector, such as Mindray Medical and WuXi AppTec, are rated as "Outperform" with strong projected earnings growth over the next few years [4][71] - Mindray Medical is expected to achieve a net profit of 116.7 billion in 2024, with a PE ratio of 23.5 [4] - WuXi AppTec is projected to have a net profit of 93.5 billion in 2024, with a PE ratio of 19.6 [4]

Group 1 - In May, a total of 876 private equity managers participated in research on A-share listed companies, covering 494 stocks across 90 Shenwan secondary industries, with a total of 2,544 research instances [1] - 25 stocks received significant attention from private equity institutions, with research frequency exceeding 20 times; specifically, 17 stocks were researched 20-29 times, and 8 stocks had research frequency of at least 30 times [1] - 30 Shenwan secondary industries were researched at least 20 times, with 15 industries researched 20-49 times, 9 industries researched 50-99 times, and 6 industries exceeding 100 research instances [1] Group 2 - The semiconductor industry was the most favored by private equity research, with 30 stocks receiving a total of 226 research instances [1] - Other notable industries included medical devices, general equipment, automation equipment, specialized equipment, and chemical pharmaceuticals, each with research instances exceeding 100, and each industry having more than 10 stocks researched [1]

Group 1 - The report highlights that the pharmaceutical index has shown positive returns across most of the six sub-industries, indicating a strong performance in the sector [1][9]. - The draft of the "Best Practice Framework for AI in Pharmacovigilance" was released on May 1, aiming to guide the development and application of AI in monitoring adverse drug reactions. This technology is expected to bring revolutionary improvements to drug safety monitoring, although a risk-oriented regulatory and governance system is necessary [2][7]. - According to the "China Pharmacovigilance Industry Research Report," the Chinese pharmacovigilance market is experiencing significant growth, with 2.419 million adverse drug reaction reports filed in 2023, reflecting an improvement in monitoring capabilities [2][8]. Group 2 - The report notes that the global pharmacovigilance market was valued at 58.568 billion in 2022 and is projected to grow at a CAGR of 10.02%, reaching approximately 103.894 billion by 2028 [8]. - The report emphasizes that the domestic AI healthcare models are rapidly developing, and the pharmacovigilance industry is expected to continue its strong growth trajectory, necessitating the establishment of a comprehensive regulatory framework [8]. - The report indicates that the innovation drug sector is entering a harvest period, supported by strong policy backing and innovation-driven growth, which is expected to enhance the overall performance of the pharmaceutical sector [16][20].